DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 55 filers reported holding DANAHER CORPORATION in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.4%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $2,956,314 | +1.9% | 12,779 | +9.3% | 1.72% | -6.6% |
| Q3 2023 | $2,901,768 | +10.7% | 11,696 | +7.0% | 1.85% | +11.7% |
| Q2 2023 | $2,622,450 | -11.0% | 10,927 | -6.5% | 1.65% | -16.3% |
| Q1 2023 | $2,945,539 | -4.7% | 11,687 | +0.3% | 1.98% | -9.6% |
| Q4 2022 | $3,091,803 | +10.3% | 11,649 | +7.3% | 2.19% | +7.6% |
| Q3 2022 | $2,804,000 | +8.5% | 10,855 | +6.5% | 2.03% | +21.6% |
| Q2 2022 | $2,585,000 | -10.5% | 10,196 | +3.6% | 1.67% | +1.5% |
| Q1 2022 | $2,887,000 | -28.3% | 9,842 | -19.6% | 1.65% | -18.2% |
| Q4 2021 | $4,029,000 | +11.4% | 12,244 | +3.1% | 2.01% | -0.8% |
| Q3 2021 | $3,616,000 | +12.3% | 11,877 | -1.0% | 2.03% | +9.9% |
| Q2 2021 | $3,221,000 | +22.8% | 12,002 | +3.0% | 1.85% | +13.6% |
| Q1 2021 | $2,622,000 | +8.2% | 11,649 | +6.7% | 1.62% | +3.4% |
| Q4 2020 | $2,424,000 | +15.6% | 10,913 | +12.1% | 1.57% | +2.3% |
| Q3 2020 | $2,096,000 | +26.8% | 9,734 | +4.1% | 1.54% | +1.9% |
| Q2 2020 | $1,653,000 | +29.2% | 9,347 | +1.1% | 1.51% | +3.9% |
| Q1 2020 | $1,279,000 | – | 9,244 | – | 1.45% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |